NovoCure (NVCR) Enterprise Value (2014 - 2026)

NovoCure has disclosed Enterprise Value across 13 years of filings, most recently posting -$432.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$432.0 million, up 53.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$432.0 million (up 53.5% YoY), and the FY2025 annual result was -$103.4 million, up 89.23% from the prior year.
• Enterprise Value came in at -$432.0 million for Q1 2026 at NovoCure, down from -$103.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$103.4 million in Q4 2025 to a low of -$969.4 million in Q4 2022.
• The 5-year median for Enterprise Value is -$432.0 million (2026), against an average of -$555.8 million.
• Across the five-year window, Enterprise Value slumped 366.22% in 2024 and soared 89.23% in 2025, its largest moves.
• NovoCure's Enterprise Value stood at -$969.4 million in 2022, then gained by 6.07% to -$910.6 million in 2023, then decreased by 5.41% to -$959.9 million in 2024, then jumped by 89.23% to -$103.4 million in 2025, then sank by 317.84% to -$432.0 million in 2026.
• The last three Enterprise Value figures came in at -$432.0 million (Q1 2026), -$103.4 million (Q4 2025), and -$344.6 million (Q3 2025), per Business Quant data.